It is also the only treatment restricted to the central nervous system (CNS) of SMA patients, who receive repeated intrathecal injections of this SMN2 splicing–modifying antisense nucleotide, consisting of four loading doses in the first two months of treatment and one maintenance dose every four months afterward [11,12,13]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.